ArticleLung cancer (Amsterdam, Netherlands)2019
Understanding patients' values and preferences regarding early stage lung cancer treatment decision making.
Article in Lung cancer (Amsterdam, Netherlands), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC.The oncologist · 2025Pooled it
- Quantitative Preferences for Lung Cancer Treatment from the Patients' Perspective: A Systematic Review.The patient · 2020Pooled it
- Recommendations for the development of an integrated lung cancer care process: an expert consensus report.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The elicitation of quality of life preferences for lung cancer treatment from the perspective of patients and treating physicians: results of two discrete choice experiments.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Best supportive care in stage I-III non-small cell lung cancer: survival by reason for curative treatment omission in a real-world study population.Translational lung cancer research · 2026Article
- Shared Decision-Making During Pulmonary Arterial Hypertension Therapy Selection: A Patient and Clinician Survey.Pulmonary circulation · 2026Article
- Improving Decision-Making Encounters in Lung Cancer Treatment: Feasibility and Acceptability of a Low-Literacy Conversation Tool (iDECIDE).CHEST pulmonary · 2025Article
- Curative intent therapy of stage I-III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms.Journal of thoracic disease · 2025Article
- Cancer patient preferences for traditional Chinese medicine treatment: a discrete choice experiment study.BMC complementary medicine and therapies · 2025Article
- We Need to Talk About Quality of Life with Cancer Patients: Primum Non Nocere in Oncology.Medicina (Kaunas, Lithuania) · 2025Article
- Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial.Future oncology (London, England) · 2025Article
- Quality of life outcomes after robotic-assisted and video-assisted thoracoscopic surgery for early-stage non-small cell lung cancer.JTCVS open · 2025Article
- Change in quality of life of stage IA non-small cell lung cancer after surgery or radiation therapy.Journal of thoracic disease · 2024Article
- Integrating evidence-based communication principles into routine cancer care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Decision Regret among Patients with Early-stage Lung Cancer Undergoing Radiation Therapy or Surgical Resection.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2023Article
- Show me the roads and give me a road map: Development of a patient conversation tool to improve lung cancer treatment decision-making.PEC innovation · 2022Article
- Influencing factors of lung cancer patients' participation in shared decision-making: a cross-sectional study.Journal of cancer research and clinical oncology · 2022Article
- Quality of Life After Stereotactic Body Radiation Therapy or Surgery for Early-Stage NSCLC: A Systematic Review.JTO clinical and research reports · 2022Review
- Patient-clinician communication and patient-centered outcomes among patients with suspected stage I non-small cell lung cancer: a prospective cohort study.Medical oncology (Northwood, London, England) · 2022Article
- Propensity score-based analysis of stereotactic body radiotherapy, lobectomy and sublobar resection for stage I non-small cell lung cancer.Journal of radiation research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
introductionWith advances in treatments among patients with lung cancer, it is increasingly important to understand patients' values and preferences to facilitate shared decision making.
methodsProspective, multicenter study of patients with treated stage I lung cancer. At the time of study participation, participants were 4-6 months posttreatment. Value clarification and discrete choice methods were used to elicit participants' values and treatment preferences regarding stereotactic body radiation therapy (SBRT) and surgical resection using only treatment attributes.
resultsAmong 114 participants, mean age was 70 years (Standard Deviation = 7.9), 65% were male, 68 (60%) received SBRT and 46 (40%) received surgery. More participants valued independence and quality of life (QOL) as "most important" compared to survival or cancer recurrence. Most participants (83%) were willing to accept lung cancer treatment with a 2% chance of periprocedural death for only one additional year of life. Participants also valued independence more than additional years of life as most (86%) were unwilling to accept either permanent placement in a nursing home or being limited to a bed/chair for four additional years of life. Surprisingly, treatment discordance was common as 49% of participants preferred the alternative lung cancer treatment than what they received.
conclusionsAmong participants with early stage lung cancer, maintaining independence and QOL were more highly valued than survival or cancer recurrence. Participants were willing to accept high periprocedural mortality, but not severe deficits affecting QOL when considering treatment. Treatment discordance was common among participants who received SBRT or surgery. Understanding patients' values and preferences regarding treatment decisions is essential to foster shared decision making and ensure treatment plans are consistent with patients' goals. Clinicians need more resources to engage in high quality communication during lung cancer treatment discussions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.